NovoCure (NASDAQ:NVCR) is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.
Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire. The company entered the public markets with a Nasdaq IPO in December 2015, expanding its ability to fund clinical research and commercial deployment of its TTFields technology.
Its flagship device, Optune, received regulatory approvals for recurrent and newly diagnosed glioblastoma multiforme in the U.S., Europe and other jurisdictions. Optune uses a portable electric field generator and transducer arrays worn on the scalp, representing a paradigm shift in the management of brain tumors. In addition to GBM, NovoCure is actively conducting clinical trials in pancreatic, ovarian, lung and liver cancers, as well as exploring applications in mesothelioma through its Optune Lua device.
NovoCure markets its products across North America, Europe and the Asia-Pacific region, emphasizing patient access programs and physician engagement to drive adoption. The leadership team is spearheaded by founder and Chief Technology Officer Yoram Palti, whose foundational research underpins the TTFields platform, supported by a seasoned executive cadre overseeing global operations, regulatory affairs and clinical development.
